Results show JN.1 vaccine reduces COVID-19 severity in adults in Japan, suggesting importance for continued vaccination.
JN.1 vaccines provided additional protection against both mild and severe outcomes among adults in Japan during circulation of KP.3 and XEC variants. These findings support continued vaccination of adults, particularly older adults, to mitigate the disease burden.
No takes yet. Share an insight, caveat, or question.
Maeda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: